ATTUNE ENSEMBLE Trademark

Trademark Overview


On Friday, April 9, 2021, a trademark application was filed for ATTUNE ENSEMBLE with the United States Patent and Trademark Office. The USPTO has given the ATTUNE ENSEMBLE trademark a serial number of 90976981. The federal status of this trademark filing is REGISTERED as of Tuesday, June 14, 2022. This trademark is owned by Blue Note Therapeutics, Inc.. The ATTUNE ENSEMBLE trademark is filed in the Computer & Software Products & Electrical & Scientific Products category with the following description:

Downloadable computer software for diagnosing and treating psychological and related physiological comorbidities of severe acute and chronic diseases
attune ensemble

General Information


Serial Number90976981
Word MarkATTUNE ENSEMBLE
Filing DateFriday, April 9, 2021
Status700 - REGISTERED
Status DateTuesday, June 14, 2022
Registration Number6762534
Registration DateTuesday, June 14, 2022
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 4, 2022

Trademark Statements


Goods and ServicesDownloadable computer software for diagnosing and treating psychological and related physiological comorbidities of severe acute and chronic diseases

Classification Information


International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateSunday, July 18, 2021
Primary Code009
First Use Anywhere DateFriday, December 31, 2021
First Use In Commerce DateFriday, December 31, 2021

Trademark Owner History


Party NameBlue Note Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94104

Party NameBlue Note Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94104

Party NameBlue Note Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94104

Trademark Events


Event DateEvent Description
Wednesday, December 1, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 13, 2021NEW APPLICATION ENTERED
Sunday, July 18, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 29, 2021ASSIGNED TO EXAMINER
Wednesday, December 15, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 4, 2022PUBLISHED FOR OPPOSITION
Tuesday, January 4, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, March 27, 2022SOU TEAS EXTENSION RECEIVED
Sunday, March 27, 2022SOU EXTENSION 1 FILED
Sunday, March 27, 2022SOU EXTENSION 1 GRANTED
Monday, March 28, 2022TEAS STATEMENT OF USE RECEIVED
Monday, March 28, 2022TEAS REQUEST TO DIVIDE RECEIVED
Monday, March 28, 2022DIVISIONAL REQUEST RECEIVED
Tuesday, March 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 15, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 21, 2022DIVISIONAL PROCESSING COMPLETE
Monday, March 28, 2022USE AMENDMENT FILED
Thursday, April 21, 2022STATEMENT OF USE PROCESSING COMPLETE
Tuesday, May 10, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 11, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 14, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, June 14, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, August 8, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Thursday, August 8, 2024WITHDRAWAL OF ATTORNEY GRANTED